Senators Pressure FTC To Scrutinize CVS Caremark
Five U.S. senators have sent letters to the Federal Trade Commission asking the commission to look more closely at the business practices of CVS Caremark and even to re-examine its approval of the merger between the drug store chain and the pharmacy benefit manager
More from Archive
More from Pink Sheet
Among those now leaving the US FDA’s biologics center is Lola Fashoyin-Aje, who was considered a rising star at the agency when she became director of the Office of Therapeutic Products’ Office of Clinical Evaluation in 2024.
Trial sponsors in Germany should start preparing negotiation strategies to tackle difficult discussions with trial sites over standardized clauses.
Newly proposed legislation for bolstering the EU’s drug manufacturing capacity and reducing its overreliance on foreign manufacturers includes a number of measures, such a requirement for EU countries to prioritize the security of supply over price when procuring drugs.